Having genetic markers associated with lower baseline bone density or faster bone turnover does not predict exact GLP-1 outcomes, but can support a more personalized monitoring strategy
This lack of uniformity compromises meta-analyses and hinders cross-study comparisons of phytochemical efficacy
Investigations focus on molecular mechanisms and assay readouts only
Co-authors of the research, Dinabel Peralta-Reich, MD, and Alexandra Filingeri DCN, RCN, explained the key findings to Medical News Today: This study measured body compositionspecifically body fat mass (in pounds), muscle mass (in pounds), and total body weight (in pounds)in patients at baseline, 3 months, and 6 months while taking GLP/GIP weight loss medications
Tirzepatide can be used safely in patients with Hashimoto's who meet obesity treatment criteria, provided thyroid function is optimized and contraindications are excluded (personal or family history of medullary thyroid carcinoma or MEN2)